Profol

Quick links to important sections

Profol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Profol

Quick Facts

Property Description
Active ingredient Propofol
Form Intravenous emulsion (most common)
Pharmacological class General Anesthetic / Short-acting Hypnotic
Common use Induction and maintenance of anesthesia
Origin Synthetic (Phenol derivative)

What Type of Medicine is Propofol?

Profol, which contains the active substance Propofol, is fundamentally classified as a general anesthetic and a short-acting hypnotic. This prescription-only medicine is a synthetic compound and belongs to the non-barbiturate class of sedative-hypnotics. Its categorization highlights its primary function: inducing a controlled, reversible state of deep unconsciousness for medical purposes. Propofol is utilized as an intravenous agent for this purpose globally.


Composition and Physical Form of Profol

The active ingredient is Propofol, a chemically specific phenol derivative identified as 2,6-diisopropylphenol. Since this molecule is highly lipid-soluble, meaning it does not readily dissolve in water, the medication is most commonly prepared as a sterile, white, milky intravenous emulsion for delivery. This unique dosage form is a single-ingredient product where the active substance is suspended in a lipid-based vehicle containing components like soybean oil and purified egg lecithin, ensuring administration via the intravenous (IV) route.


The General Purpose of This Anesthetic

The general purpose of Propofol is to facilitate rapid loss of consciousness and maintain deep, controlled sleep states during medical procedures. Due to its action as a powerful Central Nervous System (CNS) depressant, Propofol is used for the induction and maintenance of general anesthesia in operating rooms—a typical scenario being administration before a major surgical intervention. Furthermore, its characteristic rapid onset and short duration of action make it a tool for providing precise sedation to critically ill patients who require mechanical ventilation or for patients undergoing various diagnostic procedures. Propofol is considered an essential component in modern surgical and critical care settings.

Regulatory References

  1. Propofol Injection: MedlinePlus Drug Information
  2. Propofol - StatPearls - NCBI Bookshelf
  3. Propofol - eEML - Electronic Essential Medicines List

What side effects are possible with Profol?

Official Safety Profile and Adverse Reactions

The safety profile for Profol (Propofol) is rigorously documented by regulatory authorities (e.g., FDA, EMA) and is organized by the type and frequency of adverse events observed during clinical use.

Commonly Documented Adverse Reactions

Adverse events classified as common (occurring in at least 1 in 100 patients) typically involve the cardiovascular and respiratory systems. These include hypotension (a decrease in blood pressure), bradycardia (a slowed heart rate), and transient apnea (a temporary pause in breathing) upon induction. Pain at the injection site is also frequently reported.

Serious Adverse Reactions and Safety Concerns

The official labeling highlights rare but critical safety concerns, including Propofol Infusion Syndrome (PRIS), a serious condition associated with prolonged, high-dose infusions, characterized by severe metabolic acidosis, rhabdomyolysis, and organ failure. Severe anaphylaxis (allergic reaction) is also documented. Due to its lipid formulation, strict aseptic technique is mandated to prevent microbial contamination and subsequent sepsis.

Population-Specific Safety Limitations

Specific restrictions apply to certain patient groups. Profol is contraindicated for long-term sedation in pediatric patients (under 16 years of age) in the Intensive Care Unit (ICU) due to the risk of PRIS. Older adults often require lower doses due to heightened sensitivity to cardiorespiratory depression. Safety data concerning use during pregnancy and lactation are generally limited, necessitating careful assessment.

Exposure-Related Patterns

The most significant adverse pattern is the dose-dependency of cardiovascular and respiratory effects, where higher blood concentrations (resulting from rapid bolus or infusion) increase the risk of adverse events. The risk of PRIS is linked to prolonged high-dose exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Profol (Propofol) is defined by severe, dose-dependent effects on vital systems and a specialized syndrome associated with high-dose use.

Overdosage is primarily characterized by acute cardiorespiratory depression, specifically documented in regulatory labeling as arterial hypotension (low blood pressure) and apnea (cessation of breathing) [FDA]. The risk of these effects is heightened in elderly or debilitated patients.

Severe Outcomes Documented in Official Labeling
Propofol Infusion Syndrome (PRIS): Associated with prolonged, high-rate infusions, PRIS is a severe, life-threatening derangement characterized by severe metabolic acidosis, rhabdomyolysis, and cardiac failure [FDA/SmPC].
Cardiovascular Collapse: Potential progression to asystole (cardiac arrest) [FDA].

When Immediate Medical Help is Required

Any suspected overdose requires immediate medical attention by a physician trained in intensive care or anesthesia. Regulatory guidance states that Profol should only be administered where facilities for the maintenance of a patent airway and artificial ventilation with oxygen are immediately available [SmPC].

  • Mandated Action: Respiratory depression must be managed with artificial ventilation, and circulatory depression requires support using plasma expanders and pressor agents.
  • Antidote: There is no specific antidote for Profol overdosage; management is restricted entirely to symptomatic and supportive treatment.

Therapeutic Uses of Profol

What Profol Treats: Main Uses and Benefits

The primary purpose of Profol, which contains the active substance Propofol, is applied in addressing symptoms related to consciousness, motor activity, and neurological excitability. This medication is commonly used across therapeutic domains where short-term symptomatic assistance is needed for acute or disruptive symptom patterns. The medicine is relevant for easing symptoms associated with General Anesthesia (induction and maintenance), providing sedation for patients requiring mechanical ventilation in the ICU, and providing sedation for diagnostic and surgical procedures.

Controlled Deep Unconsciousness for Surgery and Procedures

Propofol is widely used across conditions presenting with acute episodes, serving to help suppress awareness and moderate symptoms related to physical discomfort during interventions. The benefit contributes to a state of deep hypnosis which is necessary for procedures to proceed and may contribute to patient comfort, helping maintain a sense of stability when symptoms are more noticeable.

Supportive Sedation and Neurological Management

This medicine is also applied in clinical settings that involve acute or unstable symptom patterns, particularly to address severe agitation and motor activity experienced by critically ill patients. Furthermore, it is relevant for easing groups of symptoms associated with increased neurological activity, such as is applied in addressing refractory status epilepticus or significantly elevated intracranial pressure (ICP), assisting with maintaining functional stability.


Quick Fact: Relief for Acute Neurological Stress

Propofol is commonly used to manage neurological symptoms linked to organ-specific functional stress, specifically by supporting the process of reducing high pressure within the skull.

Eligibility and Restrictions for Use

Profol eligibility is strictly defined by regulatory documents based on patient age, physical condition, and known allergies.

Contraindicated Populations

Use of Profol is absolutely contraindicated in patients with a known hypersensitivity to the active substance propofol or to egg or soy products found in the intravenous emulsion. The medicine is also contraindicated for sedation in the Intensive Care Unit (ICU) setting for all pediatric patients 16 years of age or younger. Additionally, the official label states it must not be used for obstetric anesthesia, including labor and delivery.

Age- and Condition-Based Restrictions

Adults are generally approved for all labeled uses. However, use is not recommended for general anesthesia in children under 3 years old for induction or under 2 months old for maintenance. For older adults and patients with an impaired physical status, administration must be restricted to lower doses given at a slower rate. Use in pregnant women is not recommended unless the potential benefit outweighs the risk. Women should also not breastfeed for 24 hours after receiving the medicine. Caution is required for patients with disorders of fat metabolism.

What should I know about interactions with other medicines?

Profol (Propofol) can interact with a wide array of other medicines, primarily by causing additive effects that increase the risk of adverse reactions, particularly pronounced sedation, respiratory depression, and significant drops in blood pressure (hypotension). Due to its rapid onset and potency, these interactions often require dosage adjustments by healthcare professionals.

Synergistic Central Nervous System (CNS) Depressants

The co-administration of Profol with other CNS depressants generally results in synergistic effects, meaning the combined impact is greater than the sum of the individual drugs. Patients must inform their healthcare provider about all medications they are taking, especially those that cause drowsiness or slow breathing. Key interacting drug classes include:

  • Opioid Analgesics: Drugs such as fentanyl, alfentanil, or remifentanil can significantly potentiate the sedative and respiratory depressant effects of Profol, often requiring lower induction doses of Profol.
  • Benzodiazepines: Medicines like diazepam, lorazepam, or midazolam increase the depth and duration of sedation and can prolong the effects of Profol.
  • Other Sedatives/Anesthetics: Including inhalational anesthetics and barbiturates, which also contribute to CNS and cardiorespiratory depression.

Cardiovascular Medications

Profol itself is known to cause a dose-dependent decrease in blood pressure. This hypotensive effect can be enhanced when co-administered with other drugs that lower blood pressure, such as:

  • Antihypertensives: Certain classes of blood pressure medication, like Angiotensin-Converting Enzyme (ACE) inhibitors, may increase the likelihood and severity of hypotension during Profol administration, requiring careful monitoring and potential management by the anesthesia provider.

Mechanism of Action

How Profol Works: Mechanism of Action

Propofol's mechanism involves the direct modulation of key neural and systemic regulatory pathways.


Central Enhancement of Inhibitory Brain Signaling

Propofol's core action is achieved by Positive Allosteric Modulation of the GABA A receptor, the primary molecular target in the Central Nervous System (CNS). This potentiation significantly amplifies the effect of the inhibitory neurotransmitter GABA, leading to a prolonged opening of the chloride ion channel. This mechanistic cascade drives the nerve cell into a state of hyperpolarization (reduced excitability), producing a prompt, widespread Global CNS Depression (a state of reduced neuronal activity).


Modulation of Cerebral Energy and Perfusion

The widespread depression of neuronal activity intrinsically leads to a dose-dependent reduction in the brain's metabolic demand, specifically the cerebral metabolic rate for oxygen ( CMRO2). This mechanistic consequence is followed by a proportional decrease in cerebral blood flow. The decrease in cerebral blood flow consequently lowers intracranial pressure.


Inherent Systemic Vascular and Respiratory Modulation

Propofol's mechanism extends beyond the CNS to influence vascular autonomic tone and central respiratory control. This leads to peripheral vasodilation and a decrease in systemic vascular resistance, consequently reducing blood pressure. Furthermore, the mechanism blunts the brainstem's sensitivity to rising levels of carbon dioxide. This systemic consequence reflects the mechanism's coupling of CNS depression with concurrent cardiovascular and respiratory modulation.

Dosage and Administration Information

Propofol (Profol) is an intravenous agent whose administration is governed by strict, specific guidelines to ensure precise use in clinical settings.

How to Use Profol: Official Administration Guidelines

The principles for using Propofol are defined by the required Intravenous (IV) route and weight-based dosing. The medication is administered either as a single rapid bolus to initiate its effect (induction of anesthesia) or as a continuous infusion to maintain a steady effect (maintenance of anesthesia or prolonged ICU sedation).


Key Dosing and Administration Parameters

Parameter Standard Adult Usage Principle Population Adjustments
Route & Form Administered exclusively via Intravenous route as an emulsion. N/A
Induction Dose Typically 1.5 to 2.5 mg/kg body weight, administered by injection. Older Adults require a reduced starting dose and a slower rate of administration to avoid rapid effects.
Maintenance Dose Continuous infusion ranging from 100 to 200 mu g/kg/minute (6 to 12 mg/kg/hour), titrated to effect. Pediatric Patients (ge 3 years) may require higher induction doses (e.g., 2.5 to 4 mg/kg) than adults.
ICU Sedation Continuous infusion, typically 5 to 50 mu g/kg/minute (0.3 to 3.0 mg/kg/hour). N/A

Procedural Requirements and Handling

The physical administration of the Propofol emulsion is subject to specific constraints. Strict aseptic technique is mandatory during preparation and use due to the product's lipid composition. The medication must generally not be mixed with other agents, and if dilution is required, only 5% Dextrose Injection, USP, is used. Furthermore, any unused portion of the emulsion, along with the administration tubing, must be discarded within 12 hours of opening the vial, enforcing a time-bound use restriction. This entire process is intended only for supervised medical settings.

Recent Clinical Evidence

Research evidence / Overview of studies for Profol

Profol, which contains the active substance Propofol, was studied for its use in several acute medical settings. This overview describes the structure of the evidence, the types of studies conducted, and the research questions they addressed, drawing only on authoritative regulatory and peer-reviewed sources.


Evidence for Use in General Anesthesia and Procedures

The core evidence structure for Propofol use in general anesthesia includes numerous Randomized Controlled Trials (RCTs) and subsequent large-scale Systematic Reviews. These studies research examined a wide range of adult and pediatric populations undergoing surgical and diagnostic procedures. Researchers focused on measuring short-term outcomes such as the time needed to induce unconsciousness and the time required for patients to awaken. Propofol was observed in studies that measured the time needed to induce unconsciousness following intravenous administration. Research highlights measurements showing that awakening times were shorter in some trials compared to those recorded for older intravenous or inhaled anesthetic options. Research is ongoing to better characterize its use alongside contemporary options.


Evidence for Use in Intensive Care Unit (ICU) Sedation

Propofol was evaluated in the critical care setting for studies examining controlled sedation in patients who require mechanical ventilation. The research base includes RCTs that compared Propofol to other sedative medications, as well as large Observational Studies. Studies monitored outcomes focusing on how long patients remained on the mechanical ventilator (duration of ventilation) and the total time spent in the ICU. Data show patterns related to successful achievement of target sedation levels across multiple studies. However, when comparing Propofol to other newer non-benzodiazepine sedatives, the findings were mixed regarding outcomes like total ICU length of stay, and evidence quality varies across studies based on the specific patient population included.


Areas of Research Uncertainty and Study Limitations

Evidence for the use of Propofol in acute neurological crises, such as refractory status epilepticus or managing significantly elevated intracranial pressure (ICP), primarily comes from Observational Studies. Studies monitored outcomes such as the cessation of clinical seizure activity and direct measurements of the pressure within the skull. The certainty remains low due to the lack of large-scale RCTs in these acute settings. Furthermore, long-term effects are not fully established across all indications, and research is ongoing to better understand potential systemic effects related to prolonged, continuous infusions in critically ill patients.

Frequently Asked Questions (FAQ)

Common questions about Profol (FAQ)

Q: How long do the effects of a single dose of Profol typically last?

A: Profol acts very quickly; official information indicates that the onset of effect is rapid, typically occurring within approximately 40 seconds of injection. The drug has a very short duration of action, which is due to its rapid redistribution from the blood into the body's tissues.

Q: Can Profol be used for sedation in children, and if so, at what age?

A: Regulatory information indicates that Profol can be used to maintain general anesthesia in pediatric patients as young as 2 months of age, and for induction in patients 3 years or older. However, it is generally not recommended for long-term sedation in the Intensive Care Unit (ICU) for children 16 years of age or younger.

Q: Does Propofol accumulate in the body after prolonged use in the ICU?

A: If continuous, high-level infusions are given over an extended period, the drug can redistribute into the body's tissues. This process of redistribution can slow down the recovery time after the infusion has been discontinued.

Q: Is it true that Profol may affect brain development in very young children?

A: Studies in developing animals have shown that prolonged exposure to anesthetic and sedation drugs can lead to neurotoxicity (injury to brain cells). Official labels carry warnings, and the medication's use is restricted in specific pediatric populations.

Q: Does the use of Profol require a mechanical ventilator (breathing machine)?

A: An induction dose of Profol is known to cause transient apnea, which is a temporary pause in breathing. When used for ICU sedation, the medication is specifically indicated for adult patients who are already intubated and require mechanical ventilation.

Q: How soon after receiving Profol can a breastfeeding mother typically resume nursing?

A: Official information states that small quantities of Profol are excreted into human milk. Official guidance advises that women generally not breastfeed for 24 hours after administration, and any milk produced during this period is recommended to be discarded.

Q: What is the typical recovery profile after Profol compared to older general anesthetics?

A: Studies and official information indicate that recovery after Profol administration is generally rapid. This recovery is often associated with less frequent side effects, such as drowsiness, nausea, or vomiting, compared to some older anesthetic agents.

Q: How does the formulation of Profol (lipid emulsion) relate to the risk of infection?

A: Profol is formulated as a lipid (fat) emulsion, a composition that makes it susceptible to microbial contamination. Therefore, strict sterile handling techniques are mandatory during preparation and use to prevent the risk of sepsis.

Q: What research exists about Profol's potential as a sleep aid for critically ill patients?

A: The use of Profol in the critical care setting is for sedation, which aims to maintain a controlled, deep rest state in patients who are mechanically ventilated. The medication is officially indicated for this specific purpose.

Q: How does the rapid redistribution of Profol in the body explain its short duration of action?

A: The short duration of effect is explained by the drug's rapid redistribution. After injection, the Profol quickly moves out of the bloodstream and is taken up by tissues, which quickly lowers the concentration in the brain, allowing the patient to awaken quickly.

Q: What are the most common temporary side effects people notice right after receiving Profol?

A: Official safety data notes that commonly reported post-procedural effects may include headache, nausea, or vomiting. The overall recovery profile is typically favorable.

Q: Is it normal to feel pain or a burning sensation where the Profol is injected?

A: Pain at the injection site is listed in regulatory documents as a very common adverse reaction. This sensation is reported most frequently when the medication is administered into smaller veins.

Q: What are the signs of a severe allergic reaction to Profol?

A: Severe allergic reactions, including anaphylaxis, are possible and documented in official sources. Signs may include a rash, hives, swelling of the face, mouth, or throat, or trouble breathing or swallowing.

Q: Can Profol cause vivid or unusual dreams during the sedation or recovery process?

A: Official information indicates that during recovery, patients may rarely experience transient excitatory phenomena. This can include delirium or hallucinations.

Q: Does alcohol consumption interact dangerously with the effects of Profol?

A: Official warnings state that co-administration with alcohol can increase nervous system side effects of the medication, such as dizziness, drowsiness, and difficulty concentrating.

Q: Are there any common over-the-counter supplements or herbal products that should be mentioned before receiving Profol?

A: Regulatory guidance advises patients to inform their healthcare providers about all medications they are taking, which includes vitamins and herbal products. Co-administration may sometimes require adjustments to the Profol dose or special patient monitoring.

Q: What is the connection between Profol use and high cholesterol or triglycerides?

A: Because Profol is formulated within a fat-based lipid emulsion, it may cause elevations in serum triglyceride levels in some patients. Monitoring is advised for patients who have risk factors for high lipid levels.

Q: Should patients with a history of seizures or epilepsy avoid Profol?

A: Official safety information recommends that Profol should be used with caution in patients with a history of seizures or epilepsy. This is because administration of the drug may potentially increase the risk of seizure activity.

Q: Can Profol be used in pregnant women, and does it cross the placenta?

A: Official sources confirm that Profol does cross the placenta. Because of this, its use is generally not recommended in pregnant women unless the potential benefit is considered to outweigh the risks.

Q: Is Profol linked to causing nausea or vomiting after a procedure?

A: While Profol is often associated with a lower incidence of nausea and vomiting compared to some older anesthetic agents, these side effects are still listed in official documentation as less common possibilities after a procedure.

Q: Does Profol cause 'green urine' in some patients, and is this dangerous?

A: Official reports indicate that green discoloration of the urine has been observed as an exceedingly rare side effect in some patients. Regulatory information suggests this is generally not a clinically significant occurrence.

Q: How long should a person wait before driving or operating machinery after a procedure with Profol?

A: Regulatory guidance advises that activities requiring complete mental alertness, such as driving or operating hazardous machinery, should be avoided until the patient is certain the drug's effects have fully cleared.

Q: What is the difference between Profol 1% and Profol 2% concentrations?

A: The medicine is available in two main concentrations: 10 mg/mL (1%) and 20 mg/mL (2%). Official labeling notes that the 2% concentration is not recommended for children 3 years of age or younger because it can be difficult to accurately adjust the dose with the smaller volumes required.

Q: Can Profol affect liver or kidney function?

A: Official documents highlight that Profol Infusion Syndrome (PRIS), a rare but serious complication, is associated with both acute kidney injury and liver dysfunction. Caution and monitoring are advised for patients with existing kidney or liver conditions.

Q: Is it necessary to inform the care team about a history of pancreatitis before Profol use?

A: Official labeling advises caution when Profol is used in patients with a history of pancreatitis (inflammation of the pancreas) or other disorders related to fat metabolism. This information is important for the care team.

Q: What is the purpose of the additive disodium edetate (EDTA) in some Profol formulations?

A: Official product information states that disodium edetate (EDTA) is included in some formulations of Profol. This compound is known as a chelator, meaning it binds to trace metals.

Q: Can Profol cause muscle stiffness or unusual movements (dystonia)?

A: Regulatory information documents that Profol can cause transient, involuntary movements during administration. These can include myoclonic movements, choreoform movements, and, in rare instances, dystonia (involuntary muscle contractions).

Q: Does Profol interact with common medications like Tylenol (acetaminophen) or ibuprofen?

A: While there are no major contraindications listed for common pain relievers like acetaminophen, caution is generally advised with all central nervous system (CNS) depressants. Patients should ensure their provider knows about all medications taken.

Q: What should be monitored closely in a patient receiving a continuous infusion of Profol?

A: Continuous infusions require close monitoring for early signs of serious complications like PRIS. Key metrics to track may include serum creatine kinase (CPK), triglycerides, and arterial blood gases to check for metabolic acidosis.

Q: Is Profol usage associated with delirium or hallucinations upon waking?

A: Official documentation indicates that, rarely, patients may experience delirium or hallucinations during the recovery period as the medication wears off.

How should Profol be stored and disposed of?

How to Store and Dispose of Propofol

Propofol injectable emulsion requires strict handling and storage to maintain its stability and prevent contamination. Unopened vials must be stored at controlled room temperatures, typically between 4 C to 25 C (40 F to 77 F), and must never be frozen.

Stability and Handling Constraints

The product is for single-patient use only and must be handled using strict aseptic technique. Vials are never to be accessed more than once. Administration must begin promptly after opening and be completed within 6 to 12 hours, depending on the specific use and formulation. The product must not be used if signs of instability, such as excessive creaming or visible large droplets, are present.

Disposal Requirements

Any unused drug product remaining in the vial, reservoir, or administration tubing must be discarded at the end of the procedure or upon reaching the defined time limit. Disposal of waste material must always be carried out in accordance with local and institutional requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Profol found in:

A-Z Index: